Alhindi Y, Vaanholt LM, Al-Tarrah M, Gray SR, Speakman JR, Hambly C, et al
The reasons are structural and biochemical, not just theoretical
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2), The Lancet, 2025
Returning appetite, a temporary weight plateau, or seeing another patient use a higher dose does not mean your dose should change
How to Manage Side Effects Start low and go slow: Your provider will typically begin with a lower dose and gradually increase it to help your body adjust
Moreover, using the ubiquitin-rhodamine G (Ub-RhoG) cleavage assay, we observed that purified recombinant USP2 K447R and USP2 C276A both showed drastically lower fluorescence intensity (indicating negligible catalytic activity) compared to WT USP2, with no significant difference in fluorescence intensity between the two mutants at any time point (Fig